Matter Bio Wins FDA IND Clearance for LM-LLO-TT Trial
SAN FRANCISCO, June 10, 2026 Matter Bio has announced that the U.S. Food and Drug Administration (FDA) has cleared...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SAN FRANCISCO, June 10, 2026 Matter Bio has announced that the U.S. Food and Drug Administration (FDA) has cleared...
TORONTO, June 9, 2026 SpinaFX Medical has achieved a major regulatory milestone after receiving U.S. Food and Drug Administration...
